MaltSci 麦伴科研

Appearance

Popular Reports / pediatrics

This report is written by MaltSci based on the latest literature and research findings

What are the latest treatments for pediatric cancers? ​

Abstract ​

Pediatric cancers, while less common than adult cancers, represent a significant health challenge affecting thousands of children worldwide. Recent advancements in treatment have dramatically improved survival rates, with five-year survival now exceeding 80%. However, 10-15% of patients experience relapse or refractory disease, highlighting the need for continued innovation. This report provides a comprehensive overview of the latest treatments for pediatric cancers, focusing on traditional modalities such as chemotherapy and radiation therapy, alongside novel therapeutic approaches including immunotherapies and targeted therapies. Immunotherapy, particularly CAR T-cell therapy, has transformed the management of acute lymphoblastic leukemia (ALL) and neuroblastoma, offering hope for durable responses and potential cures. Targeted therapies are increasingly being integrated into treatment protocols, focusing on specific genetic alterations within tumors, and nucleic acid-based therapies are emerging as promising options. The report emphasizes the importance of multidisciplinary care in optimizing treatment outcomes and discusses future directions for research, including the need for enhanced access to innovative therapies. By synthesizing current knowledge and emerging trends, this report aims to inform clinicians, researchers, and policymakers about the state of pediatric cancer treatment and to identify areas where further advancements are needed.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Pediatric Cancers
    • 2.1 Epidemiology and Types of Pediatric Cancers
    • 2.2 Biological Characteristics and Challenges in Treatment
  • 3 Traditional Treatment Modalities
    • 3.1 Chemotherapy: Advances and Current Protocols
    • 3.2 Radiation Therapy: Techniques and Considerations
  • 4 Novel Therapeutic Approaches
    • 4.1 Targeted Therapies: Mechanisms and Applications
    • 4.2 Immunotherapy: CAR T-cell Therapy and Beyond
  • 5 Multidisciplinary Care in Pediatric Oncology
    • 5.1 Importance of a Collaborative Approach
    • 5.2 Role of Supportive Care and Palliative Services
  • 6 Future Directions and Research Needs
    • 6.1 Emerging Therapies and Clinical Trials
    • 6.2 Addressing Disparities in Access to Care
  • 7 Summary

1 Introduction ​

Pediatric cancers, while less common than their adult counterparts, pose a significant health challenge, affecting thousands of children worldwide each year. Recent statistics indicate that childhood cancers account for approximately 1 in 285 children in the United States, with leukemia, brain tumors, and neuroblastoma being among the most prevalent types [1]. Over the past several decades, substantial advancements in treatment have led to an impressive increase in survival rates, with the five-year survival rate for pediatric cancers now exceeding 80% [2]. However, despite these advancements, a notable proportion of patients (10-15%) experience relapse or develop refractory disease, underscoring the urgent need for continued innovation in therapeutic strategies [1].

The significance of this research lies not only in improving survival rates but also in enhancing the quality of life for pediatric cancer survivors. Many traditional treatments, such as chemotherapy and radiation, can lead to long-term health issues, prompting a shift towards more targeted therapies that minimize adverse effects [3]. The evolution of treatment paradigms has been influenced by a deeper understanding of the biological characteristics of pediatric tumors, which often exhibit unique genetic and molecular profiles compared to adult cancers [4]. This knowledge has catalyzed the development of novel therapeutic approaches, including immunotherapies, targeted therapies, and precision medicine, which are increasingly being integrated into clinical practice [5].

Currently, the landscape of pediatric cancer treatment is rapidly evolving, with ongoing research focusing on various innovative strategies. Traditional modalities, such as chemotherapy and radiation therapy, remain foundational in treatment protocols. However, the advent of immunotherapy, particularly CAR T-cell therapy, has transformed the management of specific malignancies, such as acute lymphoblastic leukemia (ALL) [4]. Furthermore, targeted therapies aimed at specific genetic alterations are showing promise in improving outcomes for patients with various types of pediatric cancers [5].

This report is structured to provide a comprehensive overview of the latest treatments available for pediatric cancers. It begins with an overview of pediatric cancers, including their epidemiology and biological characteristics, followed by a detailed examination of traditional treatment modalities, such as chemotherapy and radiation therapy. The report then delves into novel therapeutic approaches, highlighting the mechanisms and applications of targeted therapies and immunotherapies, including CAR T-cell therapy and other innovative strategies. Additionally, the importance of multidisciplinary care in optimizing treatment outcomes will be discussed, emphasizing the role of collaborative approaches in enhancing patient care [6]. The report will conclude by addressing future directions and research needs, particularly in the context of emerging therapies and the challenges related to access to care for pediatric patients [7].

By synthesizing current knowledge and emerging trends, this report aims to inform clinicians, researchers, and policymakers about the state of pediatric cancer treatment and to identify areas where further advancements are needed. The journey towards improved outcomes for children diagnosed with cancer is ongoing, and a commitment to innovative research and collaborative care will be essential in shaping the future of pediatric oncology.

2 Overview of Pediatric Cancers ​

2.1 Epidemiology and Types of Pediatric Cancers ​

Recent advancements in the treatment of pediatric cancers have been notable, particularly in the realm of immunotherapy and targeted therapies. Over the past few decades, the overall survival rate for childhood cancers has significantly improved, reaching over 70% for many types, with some specific conditions, such as acute lymphoblastic leukemia (ALL), exceeding a 90% survival rate (Ivanov et al. 2023) [5]. However, challenges remain, especially for high-risk patients and those with relapsed or refractory diseases, necessitating the development of novel therapeutic strategies.

Immunotherapy has emerged as a transformative approach in pediatric oncology. Monoclonal antibodies, particularly those targeting GD2 in neuroblastoma and CD19 in ALL, have shown promising results. For instance, bispecific antibodies and chimeric antigen receptor (CAR) T cells have changed the treatment landscape for refractory ALL, offering durable responses and improving survival rates (Park & Cheung 2024) [1]. The efficacy of CAR T-cell therapy, specifically, has provided a chance for cure in previously lethal conditions, underscoring the importance of immune-based therapies that target specific cancer cell markers (Bosse et al. 2020) [4].

In addition to immunotherapies, the exploration of targeted therapies has gained momentum. Molecular therapies that focus on genetic abnormalities within tumors are being increasingly integrated into treatment regimens. For example, tyrosine kinase inhibitors are now standard treatments for Philadelphia chromosome-positive ALL in pediatric patients, while other targeted agents, such as aurora kinase inhibitors and MEK inhibitors, are under clinical investigation (Ivanov et al. 2023) [5].

Furthermore, the development of nucleic acid-based therapies, including short interfering RNA (siRNA) and messenger RNA (mRNA) therapeutics, is being explored as a means to enhance anti-tumor responses (Li et al. 2022) [8]. These innovative treatments aim to target specific protein expressions and have shown promise in clinical trials, highlighting the potential for improved therapeutic outcomes in pediatric populations.

Despite these advancements, the treatment of pediatric cancers still faces hurdles. The rarity of specific cancer types in children and the complexity of their genetic profiles complicate drug development. However, regulatory initiatives in the United States and Europe are fostering a more robust environment for the study of novel anticancer therapies in children, which may lead to accelerated approvals and improved treatment options (Laetsch et al. 2021) [7].

Overall, the landscape of pediatric cancer treatment is evolving, with immunotherapies and targeted therapies at the forefront of this transformation. Continued research and collaboration are essential to address the unique challenges posed by pediatric cancers and to enhance the efficacy and safety of treatments for young patients.

2.2 Biological Characteristics and Challenges in Treatment ​

The treatment landscape for pediatric cancers has evolved significantly over recent years, driven by advancements in immunotherapy, targeted therapies, and an improved understanding of the biological characteristics of these malignancies. Pediatric cancers, primarily comprising leukemias and lymphomas, have seen substantial improvements in survival rates, yet challenges remain, particularly in treating relapsed or refractory cases.

Recent advancements in immunotherapy have emerged as promising strategies in pediatric oncology. For instance, chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy, particularly in pediatric B cell acute lymphoblastic leukemia (ALL), offering potential cures for patients with previously lethal forms of the disease (Bosse et al. 2020). Similarly, monoclonal antibodies targeting specific antigens, such as GD2 in neuroblastoma, have shown durable responses and have become integral to treatment protocols (Park & Cheung 2024).

Targeted therapies have also gained traction, particularly in the treatment of ALL. The introduction of tyrosine kinase inhibitors has been a significant advancement for Philadelphia chromosome-positive (Ph+) ALL, and agents like Blinatumomab have received regulatory approval for use in children, showcasing promising results in clinical trials (Ivanov et al. 2023). Moreover, other targeted therapies, including aurora kinase inhibitors and MEK inhibitors, are under investigation, indicating a shift towards molecularly targeted treatments that address the genetic and epigenetic abnormalities present in pediatric cancers (Ivanov et al. 2023).

The use of nucleic acid-based therapies is another emerging area of interest. These therapies, including short interfering RNA (siRNA) and messenger RNA (mRNA) treatments, aim to modulate gene expression to enhance anti-tumor responses. Recent studies highlight the potential of these approaches in targeting specific molecular pathways involved in pediatric malignancies (Li et al. 2022).

Despite these advancements, challenges persist in the development of new therapies for pediatric cancers. The rarity of specific cancer types, combined with the complexity of pediatric tumor biology, necessitates innovative clinical trial designs and collaborative research efforts. Initiatives like the 'innovative therapies for children with cancer' (ITCC) consortium aim to facilitate the evaluation of novel agents in pediatric cancer, ensuring that new treatments are developed with the unique needs of children in mind (Zwaan et al. 2010).

In summary, the latest treatments for pediatric cancers emphasize a combination of immunotherapies, targeted therapies, and novel nucleic acid-based approaches, reflecting a paradigm shift towards more personalized and effective treatment modalities. Ongoing research and clinical trials will be crucial in overcoming existing challenges and improving outcomes for children with cancer.

3 Traditional Treatment Modalities ​

3.1 Chemotherapy: Advances and Current Protocols ​

The treatment landscape for pediatric cancers has evolved significantly over recent years, with traditional chemotherapy remaining a cornerstone of therapy, particularly in low- and middle-income countries. The survival rate for pediatric cancers has improved remarkably, attributed to the expansion of FDA-approved chemotherapy drugs for children. However, the side effects associated with these treatments and the challenge of multidrug resistance (MDR) continue to pose significant obstacles to enhancing survival rates for many patients (Bo et al. 2023) [9].

Traditional chemotherapy protocols for childhood cancers often face complications due to the high toxicity associated with chemotherapeutic agents, which are frequently extrapolated from adult dosing regimens. This discrepancy underscores the need for more pediatric-specific treatment protocols. Nanotechnology has emerged as a promising avenue to reduce the toxicity of anticancer compounds, enhancing the therapeutic index of cytostatic drugs and presenting an alternative to conventional chemotherapy (Rodríguez-Nogales et al. 2018) [10].

Despite advancements in chemotherapy, the plateauing of treatment outcomes for relapsing or therapy-refractory pediatric malignancies has led to increased interest in immunotherapy approaches. These include the use of monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and other cellular immunotherapies. Several monoclonal antibodies are now FDA-approved and are considered standard practice for treating specific pediatric cancers. New cellular immunotherapy approaches, such as cancer vaccines and natural killer (NK) cell therapies, are also under investigation (Huang et al. 2015) [11].

Moreover, the advent of nucleic acid therapies, including short interfering RNA (siRNA), antisense oligonucleotides (ASO), and messenger RNA (mRNA) therapies, has opened new frontiers in the treatment of pediatric cancers. These therapeutics target specific protein expressions to achieve therapeutic effects and have shown promise in improving outcomes and quality of life for pediatric patients (Li et al. 2022) [8].

The integration of molecularly targeted agents into treatment protocols is another significant advancement. These therapies aim to address the specific genetic and epigenetic alterations present in pediatric cancers, offering the potential for more effective and less toxic treatment options compared to traditional chemotherapy (Napper and Watson 2013) [12].

In summary, while traditional chemotherapy remains a critical component of pediatric cancer treatment, the incorporation of nanomedicine, immunotherapy, and targeted therapies is reshaping the therapeutic landscape. Ongoing research and clinical trials continue to explore these innovative approaches, aiming to improve outcomes and reduce the long-term side effects associated with current treatment modalities (Butler et al. 2021) [3].

3.2 Radiation Therapy: Techniques and Considerations ​

In the realm of pediatric oncology, radiation therapy has undergone significant advancements and remains a critical component of multimodal treatment strategies. The application of ionizing radiation is pivotal in achieving high rates of local disease control, particularly in the context of various childhood cancers. The use of radiation is carefully balanced against potential late effects, such as growth retardation and the induction of secondary tumors, necessitating a nuanced approach to treatment planning and delivery.

Contemporary pediatric radiation oncology employs high-energy X-ray photons as the primary modality; however, proton beam therapy is increasingly being utilized. This shift is primarily aimed at minimizing radiation exposure to surrounding healthy tissues, thereby reducing the likelihood of adverse effects. In addition to these methods, other innovative techniques such as brachytherapy and molecular radiotherapy are being explored to optimize treatment outcomes for young patients[13].

Recent innovations in radiation therapy have transformed it from an empirical practice into a highly technical and evidence-based approach. Advances in imaging and computer technology, alongside a deeper understanding of cancer pathology and molecular biology, have facilitated the development of personalized treatment plans that cater to the unique needs of pediatric patients. These improvements have not only enhanced the efficacy of radiation therapy but have also significantly reduced the incidence of late sequelae traditionally associated with cancer treatment in children[13].

The delivery of radiotherapy to children necessitates a specialized multidisciplinary team, including radiation oncologists, therapeutic radiographers, and physicists, to ensure that treatment is administered safely and effectively. The integration of such a team is crucial in navigating the complexities of pediatric cancer treatment, where the goal is to maximize therapeutic benefit while minimizing risks[13].

In summary, radiation therapy in pediatric oncology is characterized by its evolving techniques and careful consideration of both immediate and long-term outcomes. The focus on reducing adverse effects while enhancing treatment efficacy underscores the advancements made in this field, reflecting a commitment to improving survival rates and quality of life for children diagnosed with cancer.

4 Novel Therapeutic Approaches ​

4.1 Targeted Therapies: Mechanisms and Applications ​

Recent advancements in the treatment of pediatric cancers have significantly focused on targeted therapies, which are designed to exploit specific molecular alterations within tumor cells, enhancing efficacy while minimizing toxicity. The ongoing research emphasizes the identification of unique genetic and epigenetic profiles associated with various pediatric malignancies, leading to the development of innovative therapeutic strategies.

Targeted therapies in pediatric oncology have emerged in response to the limitations of conventional treatments such as surgery, radiation, and cytotoxic chemotherapy, which often exhibit insufficient efficacy and considerable morbidity in certain tumor types. Central nervous system (CNS) tumors, for instance, remain a leading cause of cancer-related mortality in children, highlighting the urgent need for novel treatment modalities. Recent reviews have underscored the importance of understanding molecular alterations that drive tumorigenesis, thereby informing the development of targeted therapies aimed at specific cellular pathways involved in these cancers (Siegel et al., 2025) [14].

A notable shift in pediatric cancer treatment is the increasing reliance on molecularly targeted agents and immunotherapies. The introduction of these therapies aims to improve outcomes for children who do not respond to traditional cytotoxic chemotherapies, while also reducing the long-term side effects associated with such treatments (Butler et al., 2021) [3]. The utilization of immunotherapeutic strategies, including chimeric antigen receptor (CAR) T-cell therapy, has shown promising results, particularly in treating high-risk pediatric leukemias, such as acute lymphoblastic leukemia (ALL) (Lee et al., 2012) [15].

In addition to CAR T-cell therapy, other immune-based approaches, including bispecific antibodies and antibody-drug conjugates, are being actively explored in clinical trials. These strategies aim to leverage the immune system's ability to target and destroy cancer cells while minimizing collateral damage to normal tissues (Bosse et al., 2020) [4]. Furthermore, recent studies have highlighted the potential of nucleic acid-based therapies, such as short interfering RNA (siRNA) and antisense oligonucleotides (ASO), which can specifically target and modulate the expression of proteins implicated in tumor growth (Li et al., 2022) [8].

The treatment landscape for pediatric solid tumors has also evolved, with a focus on molecular profiling to identify specific mutations that can be targeted with novel therapies. Ongoing clinical trials are evaluating the effectiveness of these targeted agents, with the goal of establishing more personalized treatment plans that align with the unique genetic makeup of each child's tumor (Bertacca et al., 2023) [16].

Despite the progress, challenges remain in the development and implementation of targeted therapies for pediatric cancers. The rarity of specific pediatric cancer diagnoses often limits the number of patients available for clinical trials, complicating the assessment of new drugs. Regulatory initiatives are underway to enhance the study of novel anticancer therapies in children, emphasizing the need for a robust pipeline of innovative treatments tailored to the pediatric population (Laetsch et al., 2021) [7].

In summary, the latest treatments for pediatric cancers are increasingly characterized by targeted therapies that address the unique molecular features of childhood tumors. This shift towards precision medicine, alongside the integration of immunotherapy, is poised to enhance treatment outcomes while reducing the associated long-term toxicities of conventional therapies. The ongoing research and clinical trials in this domain are critical for further advancing pediatric oncology and improving survival rates for affected children.

4.2 Immunotherapy: CAR T-cell Therapy and Beyond ​

Recent advancements in the treatment of pediatric cancers have highlighted the significant potential of immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy. This approach has emerged as a transformative modality, particularly for hematologic malignancies, and is increasingly being explored for solid tumors as well.

Pediatric central nervous system (CNS) tumors, which are the most common solid tumors in children and a leading cause of cancer-related death, exemplify the pressing need for novel therapeutic strategies. Current standard treatments such as chemotherapy, radiation, and surgery often lead to long-term adverse effects, underscoring the necessity for innovative approaches like CAR T-cell therapy. Although CAR T-cell therapy has been approved for several hematological malignancies, its application in pediatric CNS tumors faces unique challenges, including antigen selection, tumor immunogenicity, and toxicity [17].

The landscape of CAR T-cell therapy is rapidly evolving. For instance, Tisagenlecleucel (Kymriah®) has demonstrated significant efficacy in treating relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients. However, there is a disparity in the development of CAR T-cell therapies for pediatric populations compared to adults, with only one FDA approval for pediatric applications versus six for adults by 2024 [18]. This highlights the need for tailored strategies to overcome barriers specific to pediatric oncology, including complex production logistics and restrictive patient eligibility criteria [18].

In addition to hematological malignancies, CAR T-cell therapy is being investigated for solid tumors, including pediatric brain tumors and sarcomas. Recent studies indicate promising outcomes in early trials, particularly for tumors expressing GD2 and other specific antigens [19]. The unique challenges posed by the tumor microenvironment in pediatric cancers necessitate innovative strategies to enhance the efficacy of CAR T-cell therapies [20].

Moreover, advancements in immunotherapy extend beyond CAR T-cells. Other modalities such as immune checkpoint inhibitors, cancer vaccines, and dendritic cell therapies are also being explored as potential treatments for pediatric malignancies [21]. These approaches aim to capitalize on the unique immunological characteristics of pediatric cancers, which often differ from adult cancers in terms of tumor biology and response to therapies [4].

In summary, the latest treatments for pediatric cancers are increasingly centered around immunotherapy, with CAR T-cell therapy leading the charge in transforming treatment paradigms. Despite the challenges that remain, ongoing research and clinical trials continue to explore the full potential of CAR T-cells and other immunotherapeutic strategies, paving the way for more effective and less toxic treatments for children with cancer. The focus on personalized medicine and the development of innovative therapies holds promise for improving outcomes in this vulnerable population [22].

5 Multidisciplinary Care in Pediatric Oncology ​

5.1 Importance of a Collaborative Approach ​

Recent advancements in the treatment of pediatric cancers have highlighted the importance of a multidisciplinary and collaborative approach, integrating various therapeutic modalities to improve patient outcomes. Over the last few decades, the overall survival rates for pediatric cancers have significantly increased, reaching over 80% for many conditions, but challenges remain, particularly for high-risk populations and relapsed cases [23].

Immunotherapy has emerged as a prominent treatment modality, particularly for acute lymphoblastic leukemia (ALL) and neuroblastoma. Monoclonal antibodies targeting GD2 have shown durable responses in neuroblastoma, while CD19-targeted bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T cells have transformed the treatment landscape for refractory ALL [1]. CAR T-cell therapy, in particular, has demonstrated robust efficacy, offering a chance of cure for previously lethal diseases [4].

Moreover, the incorporation of nucleic acid therapies, such as short interfering RNA (siRNA) and messenger RNA (mRNA) therapies, is gaining traction. These therapies aim to target specific protein expressions to achieve therapeutic effects, and several nucleic acid-based drugs have been approved by regulatory bodies for use in pediatric cancers [8].

Recent research also emphasizes the role of targeted therapies, which are being increasingly utilized to address the molecular underpinnings of pediatric malignancies. For instance, tyrosine kinase inhibitors have become part of the standard treatment for Philadelphia chromosome-positive ALL, while other targeted agents, including aurora-kinase inhibitors and MEK inhibitors, are currently under investigation in clinical trials for pediatric patients [5].

Furthermore, the development of immunovirotherapy represents a promising avenue for treating aggressive pediatric solid tumors. This approach leverages oncolytic viruses to elicit antitumor immune responses while directly targeting tumor cells [24].

The landscape of pediatric oncology is also evolving with the integration of pharmacogenomics, which aims to tailor treatments based on individual genetic profiles. This personalized approach seeks to minimize adverse drug reactions and enhance the efficacy of treatments [23].

In conclusion, the latest treatments for pediatric cancers encompass a variety of innovative strategies, including immunotherapy, targeted therapies, nucleic acid-based treatments, and personalized medicine approaches. A collaborative effort among clinicians, researchers, and regulatory bodies is essential to continue advancing these therapies and improving outcomes for children facing cancer.

5.2 Role of Supportive Care and Palliative Services ​

The treatment landscape for pediatric cancers has evolved significantly, driven by advancements in both therapeutic strategies and the integration of multidisciplinary care approaches. In recent years, the focus has shifted towards personalized medicine, immunotherapy, and supportive care, which are critical components in managing pediatric malignancies.

Modern therapeutic approaches in pediatric oncology primarily encompass multimodal strategies that include surgery, chemotherapy, radiation therapy, and innovative immunotherapies. According to Panuciak et al. (2022), the treatment of pediatric cancers, particularly lymphomas and leukemias, has increasingly leveraged the mobilization of the patient's immune system. Notable advancements include the use of chimeric antigen receptor T (CAR-T) cells, bispecific antibodies, and antibody-drug conjugates (ADC), which have shown promise in treating acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [6].

Additionally, nucleic acid therapies have emerged as a novel class of treatments in pediatric oncology. Li et al. (2022) highlighted the role of short interfering RNA (siRNA), antisense oligonucleotides (ASO), and messenger RNA (mRNA) in targeting specific protein expressions to achieve therapeutic effects. Over ten nucleic acid therapeutics have received approval from the FDA and EMA for various cancers, indicating a growing acceptance and efficacy of these therapies in pediatric populations [8].

Supportive care plays an essential role in the overall treatment of pediatric cancer patients. As noted by Kazak and Noll (2015), the integration of psychological support is crucial for addressing the emotional and psychological impacts of cancer diagnosis and treatment on children and their families. This includes managing procedural pain, nausea, and other treatment-related symptoms, as well as facilitating transitions to palliative care when necessary [25].

Furthermore, collaborative efforts at national and international levels have been pivotal in improving treatment outcomes. Rodriguez-Galindo et al. (2015) emphasized that over 80% of children with cancer treated with modern multidisciplinary therapies in developed countries are cured. However, challenges remain in low- and middle-income countries (LMICs), where access to quality care is limited, and the burden of disease is not fully understood due to inadequate cancer registries [26].

In summary, the latest treatments for pediatric cancers involve a combination of advanced immunotherapies, nucleic acid therapies, and comprehensive supportive care, all delivered through a multidisciplinary framework that aims to optimize patient outcomes while minimizing long-term health issues. The integration of psychological support and collaborative efforts in research and treatment delivery further enhances the effectiveness of these interventions, making them essential components of modern pediatric oncology care.

6 Future Directions and Research Needs ​

6.1 Emerging Therapies and Clinical Trials ​

Recent advancements in the treatment of pediatric cancers have highlighted the importance of immunotherapy and targeted therapies, addressing the need for innovative strategies due to the limitations of traditional chemotherapy and radiation. Over the past few decades, the overall survival rate for pediatric cancers has significantly improved, with a 5-year survival rate now reaching approximately 85% for children. However, 10%-15% of patients still experience relapse or develop refractory disease, necessitating the exploration of new treatment modalities (Park & Cheung, 2024) [1].

Immunotherapies have emerged as a promising avenue for treatment, particularly for high-risk pediatric cancers such as acute lymphoblastic leukemia (ALL) and neuroblastoma (NB). Monoclonal antibodies targeting GD2 have shown durable responses in neuroblastoma, while CD19-targeted bispecific antibodies and chimeric antigen receptor (CAR) T cells have transformed the treatment landscape for refractory ALL in children (Park & Cheung, 2024) [1]. In addition, FDA-approved monoclonal antibodies are becoming standard practice in the treatment of pediatric malignancies, with new cellular immunotherapy approaches, including CAR-modified T cells and cancer vaccines, being actively investigated in clinical trials (Huang et al., 2015) [11].

Recent research emphasizes the integration of molecular therapies alongside immunotherapies. For instance, targeted therapies such as tyrosine kinase inhibitors have been incorporated into the treatment regimens for Philadelphia chromosome-positive ALL, and novel agents like Blinatumomab have received regulatory approval for use in children (Ivanov et al., 2023) [5]. Furthermore, the development of nucleic acid-based therapies, including short interfering RNA (siRNA) and messenger RNA (mRNA), is gaining traction, with over ten nucleic acid therapeutics already approved for use in rare and genetic diseases, which may also benefit pediatric cancer patients (Li et al., 2022) [8].

The evolving landscape of pediatric oncology also includes the establishment of initiatives like the 'innovative therapies for children with cancer' (ITCC) consortium, which focuses on evaluating novel agents in preclinical models and early clinical trials, thereby enhancing the development of pediatric-specific treatments (Zwaan et al., 2010) [2]. The exploration of therapeutic cancer vaccines is another area of active research, as they aim to leverage the immune system to specifically target tumor antigens, thereby reducing off-target toxicity associated with conventional treatments (Olsen et al., 2021) [27].

Despite these advancements, challenges remain in pediatric drug development, particularly due to the rarity of specific cancer diagnoses and the complexity of pediatric tumor biology. The need for tailored dosage optimization approaches is paramount, as traditional dose-finding methods may not be applicable to newer targeted therapies that exhibit different efficacy and safety profiles (Wessel et al., 2025) [28]. Ongoing efforts in regulatory frameworks aim to facilitate the inclusion of pediatric patients in clinical trials for novel therapies, ensuring that emerging treatments are both effective and safe for this vulnerable population (Laetsch et al., 2021) [7].

In conclusion, the future directions in pediatric cancer treatment emphasize a shift towards immunotherapy, targeted therapies, and innovative drug development approaches. Continued research and clinical trials are essential to enhance the therapeutic landscape for pediatric cancers, ultimately improving survival rates and quality of life for young patients.

6.2 Addressing Disparities in Access to Care ​

Recent advancements in the treatment of pediatric cancers have been marked by a shift towards innovative therapeutic approaches, particularly immunotherapies and targeted therapies. Despite the overall increase in survival rates for pediatric cancers, which now exceed 70%, significant disparities in access to care and treatment outcomes persist, necessitating ongoing research and intervention.

Immunotherapy has emerged as a cornerstone in the treatment of various pediatric malignancies. Monoclonal antibodies targeting specific antigens, such as GD2 for neuroblastoma and CD19 for acute lymphoblastic leukemia (ALL), have demonstrated substantial efficacy, providing durable responses in patients who previously faced poor prognoses [1]. Chimeric antigen receptor (CAR) T-cell therapies have revolutionized treatment paradigms for B-cell malignancies, particularly in children with refractory or relapsed ALL, offering hope for cures in previously lethal conditions [4].

In addition to immunotherapies, the integration of targeted therapies based on genetic profiling of tumors has gained traction. Advances in understanding the molecular underpinnings of pediatric cancers have led to the development of drugs targeting specific genetic alterations. For instance, tyrosine kinase inhibitors have become part of the standard treatment for Philadelphia chromosome-positive ALL, while novel agents such as Blinatumomab have shown promise in clinical trials [5]. Furthermore, ongoing research is exploring the efficacy of immune checkpoint inhibitors and antibody-drug conjugates, which are gaining momentum in clinical applications [6].

The future directions in pediatric oncology emphasize the need for personalized medicine, focusing on the genetic and molecular characteristics of tumors to guide treatment decisions. The increasing availability of next-generation sequencing technologies is pivotal in identifying actionable mutations and tailoring therapies accordingly [29]. Moreover, there is a concerted effort to expand the clinical trials available for pediatric populations, as many novel therapies initially developed for adults are now being adapted for children [7].

Addressing disparities in access to care remains a critical challenge. While innovative therapies are being developed, their availability is often limited by geographical, economic, and systemic barriers. The establishment of collaborative networks, such as the Innovative Therapies for Children with Cancer (ITCC) consortium, aims to enhance the evaluation and accessibility of new drugs in pediatric oncology [2]. Furthermore, regulatory initiatives are encouraging pharmaceutical companies to prioritize pediatric clinical data, thereby facilitating the inclusion of children in clinical trials [7].

In conclusion, the landscape of pediatric cancer treatment is rapidly evolving, driven by advancements in immunotherapy and targeted therapies. However, to fully realize the potential of these innovations, concerted efforts must be made to address access disparities and ensure that all children benefit from the latest therapeutic options. Ongoing research is essential to continue improving treatment outcomes and quality of life for pediatric cancer patients.

7 Conclusion ​

The latest advancements in pediatric cancer treatment underscore a significant evolution in therapeutic strategies, focusing on immunotherapies, targeted therapies, and personalized medicine. Recent innovations, particularly in CAR T-cell therapy and the use of monoclonal antibodies, have transformed the management of high-risk pediatric cancers, achieving remarkable survival rates and improving outcomes for previously refractory cases. However, challenges remain, particularly for relapsed and refractory diseases, where a considerable proportion of patients still face poor prognoses. The integration of targeted therapies based on molecular profiling is enhancing treatment efficacy while minimizing long-term side effects. Furthermore, the emphasis on multidisciplinary care is essential in optimizing treatment approaches, ensuring comprehensive support for patients and their families. Future research must continue to address disparities in access to care, facilitating the inclusion of pediatric patients in clinical trials and ensuring that emerging therapies are both effective and safe for this vulnerable population. As the landscape of pediatric oncology continues to evolve, a commitment to innovative research and collaborative care will be pivotal in shaping the future of pediatric cancer treatment and improving the quality of life for young survivors.

References ​

  • [1] Jeong A Park;Nai-Kong V Cheung. Immunotherapies for Childhood Cancer.. Cold Spring Harbor perspectives in medicine(IF=10.1). 2025. PMID:39009446. DOI: 10.1101/cshperspect.a041574.
  • [2] C Michel Zwaan;Pamela Kearns;Huib Caron;Arnauld Verschuur;Riccardo Riccardi;Joachim Boos;Francois Doz;Birgit Geoerger;Bruce Morland;Gilles Vassal; . The role of the 'innovative therapies for children with cancer' (ITCC) European consortium.. Cancer treatment reviews(IF=10.5). 2010. PMID:20231057. DOI: 10.1016/j.ctrv.2010.02.008.
  • [3] Erin Butler;Kathleen Ludwig;Holly L Pacenta;Laura J Klesse;Tanya C Watt;Theodore W Laetsch. Recent progress in the treatment of cancer in children.. CA: a cancer journal for clinicians(IF=232.4). 2021. PMID:33793968. DOI: 10.3322/caac.21665.
  • [4] Kristopher R Bosse;Robbie G Majzner;Crystal L Mackall;John M Maris. Immune-Based Approaches for the Treatment of Pediatric Malignancies.. Annual review of cancer biology(IF=6.1). 2020. PMID:34113750. DOI: 10.1146/annurev-cancerbio-030419-033436.
  • [5] Anca Viorica Ivanov;Mirabela Smaranda Alecsa;Roxana Popescu;Magdalena Iuliana Starcea;Adriana Maria Mocanu;Cristina Rusu;Ingrith Crenguta Miron. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.. International journal of molecular sciences(IF=4.9). 2023. PMID:36902091. DOI: 10.3390/ijms24054661.
  • [6] Kinga Panuciak;Mikołaj Margas;Karolina Makowska;Monika Lejman. Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.. Cells(IF=5.2). 2022. PMID:35011701. DOI: 10.3390/cells11010139.
  • [7] Theodore W Laetsch;Steven G DuBois;Julia Glade Bender;Margaret E Macy;Lucas Moreno. Opportunities and Challenges in Drug Development for Pediatric Cancers.. Cancer discovery(IF=33.3). 2021. PMID:33277309. DOI: 10.1158/2159-8290.CD-20-0779.
  • [8] Yongshu Li;Bihui Huang;Zhichao Xue;Yunhua Gao;Zhenjian Zhuo. Nucleic acid therapy in pediatric cancer.. Pharmacological research(IF=10.5). 2022. PMID:36096420. DOI: 10.1016/j.phrs.2022.106441.
  • [9] Letao Bo;Youyou Wang;Yidong Li;John N D Wurpel;Zoufang Huang;Zhe-Sheng Chen. The Battlefield of Chemotherapy in Pediatric Cancers.. Cancers(IF=4.4). 2023. PMID:37046624. DOI: 10.3390/cancers15071963.
  • [10] Carlos Rodríguez-Nogales;Yolanda González-Fernández;Azucena Aldaz;Patrick Couvreur;María J Blanco-Prieto. Nanomedicines for Pediatric Cancers.. ACS nano(IF=16.0). 2018. PMID:30071163. DOI: 10.1021/acsnano.8b03684.
  • [11] Michael A Huang;Deepa K Krishnadas;Kenneth G Lucas. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.. Journal of immunology research(IF=3.6). 2015. PMID:26587548. DOI: 10.1155/2015/675269.
  • [12] Andrew D Napper;Venita G Watson. Targeted drug discovery for pediatric leukemia.. Frontiers in oncology(IF=3.3). 2013. PMID:23847761. DOI: 10.3389/fonc.2013.00170.
  • [13] Tom Boterberg;Cathy Dunlea;Semi Harrabi;Geert Janssens;Anne Laprie;Gillian Whitfield;Mark Gaze; . Contemporary paediatric radiation oncology.. Archives of disease in childhood(IF=3.2). 2023. PMID:35851293. DOI: 10.1136/archdischild-2021-323059.
  • [14] Benjamin I Siegel;Prabhumallikarjun Patil;Akul Prakash;Darren M Klawinski;Eugene I Hwang. Targeted therapy in pediatric central nervous system tumors: a review from the National Pediatric Cancer Foundation.. Frontiers in oncology(IF=3.3). 2025. PMID:40094009. DOI: 10.3389/fonc.2025.1504803.
  • [15] Daniel W Lee;David M Barrett;Crystal Mackall;Rimas Orentas;Stephan A Grupp. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research(IF=10.2). 2012. PMID:22589486. DOI: 10.1158/1078-0432.CCR-11-1920.
  • [16] Ilaria Bertacca;Francesco Pegoraro;Annalisa Tondo;Claudio Favre. Targeted treatment of solid tumors in pediatric precision oncology.. Frontiers in oncology(IF=3.3). 2023. PMID:37213274. DOI: 10.3389/fonc.2023.1176790.
  • [17] Ian Burns;William D Gwynne;Yujin Suk;Stefan Custers;Iqra Chaudhry;Chitra Venugopal;Sheila K Singh. The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues.. Frontiers in oncology(IF=3.3). 2022. PMID:35155252. DOI: 10.3389/fonc.2022.815726.
  • [18] David A Martínez-Gamboa;Rhea Hans;Eider Moreno-Cortes;Juana Figueroa-Aguirre;Juan Esteban Garcia-Robledo;Fabio Vargas-Cely;Natalie Booth;Daniela A Castro-Martinez;Roberta H Adams;Januario E Castro. CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology - A comprehensive analysis of clinical trials.. Critical reviews in oncology/hematology(IF=5.6). 2025. PMID:39900318. DOI: 10.1016/j.critrevonc.2025.104648.
  • [19] Rachael L Terry;Deborah Meyran;Emmy D G Fleuren;Chelsea Mayoh;Joe Zhu;Natacha Omer;David S Ziegler;Michelle Haber;Phillip K Darcy;Joseph A Trapani;Paul J Neeson;Paul G Ekert. Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.. Cancers(IF=4.4). 2021. PMID:34572932. DOI: 10.3390/cancers13184704.
  • [20] Padmashree Rao;Liam Furst;Deborah Meyran;Chelsea Mayoh;Paul J Neeson;Rachael Terry;Dong-Anh Khuong-Quang;Theo Mantamadiotis;Paul G Ekert. Advances in CAR T cell immunotherapy for paediatric brain tumours.. Frontiers in oncology(IF=3.3). 2022. PMID:36505819. DOI: 10.3389/fonc.2022.873722.
  • [21] Wan-Tai Wu;Wen-Ying Lin;Yi-Wei Chen;Chun-Fu Lin;Hsin-Hui Wang;Szu-Hsien Wu;Yi-Yen Lee. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.. International journal of molecular sciences(IF=4.9). 2021. PMID:33673696. DOI: 10.3390/ijms22052404.
  • [22] Andrew Dj Pearson;Claudia Rossig;Crystal Mackall;Nirali N Shah;Andre Baruchel;Gregory Reaman;Rosanna Ricafort;Delphine Heenen;Abraham Bassan;Michael Berntgen;Nick Bird;Eric Bleickardt;Najat Bouchkouj;Peter Bross;Carrie Brownstein;Sarah Beaussant Cohen;Teresa de Rojas;Lori Ehrlich;Elizabeth Fox;Stephen Gottschalk;Linda Hanssens;Douglas S Hawkins;Ivan D Horak;Danielle H Taylor;Courtney Johnson;Dominik Karres;Franca Ligas;Donna Ludwinski;Maksim Mamonkin;Lynley Marshall;Behzad K Masouleh;Yousif Matloub;Shannon Maude;Joe McDonough;Veronique Minard-Colin;Koen Norga;Karsten Nysom;Alberto Pappo;Laura Pearce;Rob Pieters;Martin Pule;Alfonso Quintás-Cardama;Nick Richardson;Martina Schüßler-Lenz;Nicole Scobie;Martina A Sersch;Malcolm A Smith;Jaroslav Sterba;Sarah K Tasian;Brenda Weigel;Susan L Weiner;Christian Michel Zwaan;Giovanni Lesa;Gilles Vassal. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.. European journal of cancer (Oxford, England : 1990)(IF=7.1). 2022. PMID:34840026. DOI: 10.1016/j.ejca.2021.10.016.
  • [23] Shahrad Rod Rassekh;Colin J D Ross;Bruce C Carleton;Michael R Hayden. Cancer pharmacogenomics in children: research initiatives and progress to date.. Paediatric drugs(IF=3.3). 2013. PMID:23529868. DOI: 10.1007/s40272-013-0021-9.
  • [24] Daniel de la Nava;Kadir Mert Selvi;Marta M Alonso. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.. Frontiers in immunology(IF=5.9). 2022. PMID:35493490. DOI: 10.3389/fimmu.2022.866892.
  • [25] Anne E Kazak;Robert B Noll. The integration of psychology in pediatric oncology research and practice: collaboration to improve care and outcomes for children and families.. The American psychologist(IF=7.2). 2015. PMID:25730721. DOI: 10.1037/a0035695.
  • [26] Carlos Rodriguez-Galindo;Paola Friedrich;Patricia Alcasabas;Federico Antillon;Shripad Banavali;Luis Castillo;Trijn Israels;Sima Jeha;Mhammed Harif;Michael J Sullivan;Thuan Chong Quah;Catherine Patte;Ching-Hon Pui;Ronald Barr;Thomas Gross. Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology(IF=41.9). 2015. PMID:26304881. DOI: 10.1200/JCO.2014.60.6376.
  • [27] Hannah E Olsen;Geoffrey M Lynn;Pablo A Valdes;Christian D Cerecedo Lopez;Andrew S Ishizuka;Omar Arnaout;W Linda Bi;Pier Paolo Peruzzi;E Antonio Chiocca;Gregory K Friedman;Joshua D Bernstock. Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies.. Neuro-oncology advances(IF=4.1). 2021. PMID:33860227. DOI: 10.1093/noajnl/vdab027.
  • [28] Kristin M Wessel;Nicole Drezner;Stacy S Shord;Mirat Shah;Marc R Theoret;Martha Donoghue. Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better.. Clinical cancer research : an official journal of the American Association for Cancer Research(IF=10.2). 2025. PMID:40325515. DOI: 10.1158/1078-0432.CCR-24-4325.
  • [29] James F Amatruda. Modeling the developmental origins of pediatric cancer to improve patient outcomes.. Disease models & mechanisms(IF=3.3). 2021. PMID:33619212. DOI: 10.1242/dmm.048930.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Pediatric Cancer · Immunotherapy · Targeted Therapy · Chemotherapy · Multidisciplinary Care

© 2025 MaltSci